Edge Therapeutics (EDGE) Competitors

Edge Therapeutics (NASDAQ:EDGE) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Which has stronger valuation & earnings, EDGE or RZLT?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edge Therapeutics	N/A	N/A	-$40.86M	N/A	N/A
Rezolute	N/A	N/A	-$51.79M	-$1.10	-3.01

Is EDGE or RZLT more profitable?

Rezolute's return on equity of -51.81% beat Edge Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edge Therapeutics	N/A	-81.29%	-56.92%
Rezolute	N/A	-51.81%	-48.05%

Does the media prefer EDGE or RZLT?

In the previous week, Edge Therapeutics had 7 more articles in the media than Rezolute. MarketBeat recorded 8 mentions for Edge Therapeutics and 1 mentions for Rezolute. Rezolute's average media sentiment score of 1.54 beat Edge Therapeutics' score of 0.00 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edge Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more volatility and risk, EDGE or RZLT?

Edge Therapeutics has a beta of 3.65, suggesting that its stock price is 265% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Does the MarketBeat Community favor EDGE or RZLT?

Edge Therapeutics received 123 more outperform votes than Rezolute when rated by MarketBeat users. However, 75.00% of users gave Rezolute an outperform vote while only 66.79% of users gave Edge Therapeutics an outperform vote.

Company	Underperform	Outperform
Edge Therapeutics	Outperform Votes 177 66.79%	Underperform Votes 88 33.21%
Rezolute	Outperform Votes 54 75.00%	Underperform Votes 18 25.00%

Do analysts recommend EDGE or RZLT?

Rezolute has a consensus target price of $8.80, indicating a potential upside of 165.86%. Given Rezolute's higher possible upside, analysts plainly believe Rezolute is more favorable than Edge Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edge Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Rezolute	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of EDGE or RZLT?

28.0% of Edge Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 37.1% of Edge Therapeutics shares are held by company insiders. Comparatively, 18.2% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Rezolute beats Edge Therapeutics on 7 of the 12 factors compared between the two stocks.